Literature DB >> 1952208

Effects of protamine on vascular smooth muscle of rabbit mesenteric artery.

T Akata1, J Yoshitake, M Nakashima, T Itoh.   

Abstract

Systemic hypotension is commonly observed in association with protamine administration after cardiopulmonary bypass. However, little information is available concerning the action of protamine on vascular smooth muscle. Thus, we investigated the action of protamine on vascular tissues using tension recording and microelectrode methods. Protamine (5-500 micrograms/ml) inhibited contractions induced by norepinephrine (NE)- or elevated K+ in a concentration-dependent manner in both endothelium-intact and -denuded strips. Protamine inhibition of NE contractions was less profound after endothelial denudation, whereas protamine inhibition of K(+)-induced contractions was less affected by prior denudation. In endothelium-intact strips, the protamine-induced inhibition was significantly reduced by inhibitors of the endothelium-derived relaxing factor pathway, including oxyhemoglobin, methylene blue, or NG-nitro-L-arginine, whereas the contractile inhibition was enhanced by superoxide dismutase. In endothelium-denuded strips, protamine inhibited Ca(2+)-induced contraction evoked in Ca(2+)-free solution containing 100 mM K+ and inhibited the NE-induced contraction under the following conditions: 1) in Ca(2+)-free solution; 2) after nifedipine treatment; and 3) after depletion of stored Ca2+ by A23187 or ryanodine. In membrane-permeabilized strips, protamine did not modify Ca(2+)-induced contraction. Protamine (50-500 micrograms/ml) did not modify the membrane potential of either endothelium-intact or -denuded strips. Furthermore, protamine irreversibly impaired acetylcholine-induced endothelium-dependent relaxant response, implying a toxic effect of protamine on the endothelium. We conclude that protamine exerts its inhibition on vascular smooth muscles in both an endothelium-dependent and -independent manner; i.e., the endothelium-dependent component is mediated probably by endothelium-derived relaxing factor, and direct smooth muscle effects are due to the inhibition of both Ca(2+)-influx and the NE-induced Ca2+ release from intracellular stores.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952208     DOI: 10.1097/00000542-199111000-00016

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

1.  Reversible block of the calcium release channel/ryanodine receptor by protamine, a heparin antidote.

Authors:  P Koulen; B E Ehrlich
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

2.  Regulation of neuronal nitric oxide synthase by histone, protamine, and myelin basic protein.

Authors:  J Hu; J Fridlund; E E el-Fakahany
Journal:  Neurochem Res       Date:  1995-04       Impact factor: 3.996

3.  Multiple actions of halothane on contractile response to noradrenaline in isolated mesenteric resistance arteries.

Authors:  J Yoshino; T Akata; K Izumi; S Takahashi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

4.  Protamine relaxes vascular smooth muscle by directly reducing cytosolic free calcium concentrations in small resistance arteries.

Authors:  Takashi Akata; Kenji Kodama; Alex S Evers; Shosuke Takahashi
Journal:  J Anesth       Date:  1996-12       Impact factor: 2.078

5.  Effects of heparin on the vasodilator action of protamine in the rabbit mesenteric artery.

Authors:  T Akata; K Kodama; S Takahashi
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

6.  Volatile anaesthetic actions on norepinephrine-induced contraction of small splanchnic resistance arteries.

Authors:  T Akata; K Kodama; S Takahashi
Journal:  Can J Anaesth       Date:  1995-11       Impact factor: 5.063

7.  Effects of phenol on vascular smooth muscle in rabbit mesenteric resistance arteries.

Authors:  T Akata; K Kodama; S Takahashi
Journal:  J Anesth       Date:  1996-03       Impact factor: 2.078

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.